
  
    
      
        Introduction_NNP
        In_IN diarthodial_NN joints_NNS ,_, cartilage_NN provides_VBZ a_DT smooth_JJ
        surface_NN that_WDT enables_VBZ joints_NNS to_TO articulate_VB and_CC to_TO withstand_VB
        compressional_NN and_CC shear_NN stress_NN [_NN 1_CD ]_NN ._. Embedded_VBN in_IN the_DT
        cartilage_NN are_VBP chondrocytes_NNS that_WDT respond_VBP to_TO biochemical_JJ and_CC
        physical_JJ stimuli_NNS to_TO maintain_VB this_DT tissue_NN ._. Cartilage_NNP is_VBZ
        primarily_RB composed_VBN of_IN type_NN II_NNP collagen_NN and_CC proteoglycan_NN ,_,
        which_WDT are_VBP synthesized_JJ by_IN the_DT chondrocytes_NNS ._. In_IN addition_NN ,_,
        chondrocytes_NNS produce_VBP enzymes_NNS ,_, such_JJ as_IN the_DT matrix_NN
        metalloproteinases_NNS (_( MMPs_NNP )_) ,_, that_DT degrade_NN the_DT cartilage_NN [_NN 2_CD ]_NN
        ._. In_IN arthritis_NN ,_, an_DT imbalance_NN of_IN these_DT processes_VBZ in_IN favour_NN
        of_IN degradation_NN results_NNS in_IN a_DT loss_NN of_IN cartilage_NN ._. For_IN the_DT
        patient_NN ,_, this_DT is_VBZ manifested_JJ as_IN a_DT degeneration_NN of_IN joint_JJ
        function_NN ,_, loss_NN of_IN mobility_NN and_CC concomitant_NN increased_VBD
        morbidity_NN and_CC mortality_NN [_NN 3_CD 4_CD ]_NN ._. For_IN the_DT clinician_NN ,_, this_DT
        imbalance_NN identifies_VBZ a_DT need_NN for_IN therapeutic_JJ agents_NNS to_TO
        prevent_VB cartilage_NN loss_NN [_NN 5_CD ]_NN ._.
        In_IN identifying_VBG targets_NNS for_IN therapeutic_JJ intervention_NN ,_, it_PRP
        is_VBZ important_JJ to_TO note_VB that_IN the_DT loss_NN of_IN collagen_NN ,_, rather_RB than_IN
        proteoglycan_NN ,_, is_VBZ correlated_JJ with_IN disease_NN severity_NN [_NN 6_CD ]_NN ._.
        Furthermore_RB ,_, whereas_IN lost_VBN proteoglycan_NN is_VBZ replaced_VBN rapidly_RB ,_,
        degraded_JJ collagen_NN is_VBZ resynthesized_JJ very_RB slowly_RB [_NN 7_CD 8_CD ]_NN ._.
        Consequently_RB ,_, understanding_NN collagen_NN degradation_NN and_CC
        providing_VBG therapeutics_NNS to_TO prevent_VB it_PRP are_VBP valuable_JJ aims_NNS ._.
        Within_IN the_DT MMP_NNP family_NN ,_, MMP-_NNP 1_CD (_( collagenase-_NN 1_LS )_) and_CC MMP-_NNP 13_CD
        (_( collagenase-_NN 3_LS )_) are_VBP expressed_VBN in_IN arthritic_JJ joints_NNS ,_, and_CC
        efficiently_RB degrade_NN type_NN II_NNP collagen_NN [_NN 9_CD ]_NN ._. MMP-_NNP 13_CD is_VBZ more_RBR
        effective_JJ than_IN MMP-_NNP 1_CD in_IN cleaving_VBG type_NN II_NNP collagen_NN ,_, but_CC it_PRP
        is_VBZ debated_VBN which_WDT is_VBZ the_DT principal_JJ collagenase_NN 
        in_IN vivo_NN [_NN 10_CD 11_CD ]_NN ._. These_DT enzymes_NNS
        have_VBP been_VBN implicated_VBN in_IN the_DT pathology_NN of_IN rheumatoid_NN
        arthritis_NN (_( RA_NNP )_) and_CC osteoarthritis_NNS (_( OA_NNP )_) ,_, and_CC have_VBP long_RB been_VBN
        therapeutic_JJ targets_NNS [_NN 12_CD ]_NN ._. Historically_NNP ,_, inhibition_NN of_IN
        MMP-active_NNP sites_NNS has_VBZ been_VBN a_DT strategy_NN ;_: however_RB ,_, with_IN
        wide-ranging_JJ side-effects_JJ and_CC lack_NN of_IN efficacy_NN ,_, these_DT
        studies_NNS are_VBP proving_VBG unfruitful_JJ in_IN providing_VBG an_DT effective_JJ
        drug_NN [_NN 13_CD ]_NN ._.
        Although_IN the_DT etiologies_NNS and_CC pathologies_NNS of_IN RA_NNP and_CC OA_NNP
        differ_VBP ,_, it_PRP is_VBZ clear_JJ that_IN in_IN both_DT of_IN these_DT diseases_NNS
        pro-inflammatory_JJ cytokines_NNS are_VBP present_JJ ,_, resulting_VBG in_IN an_DT
        inflammatory_JJ state_NN as_RB well_RB as_IN cartilage_NN degradation_NN [_NN 14_CD ]_NN
        ._. As_IN further_JJ evidence_NN for_IN the_DT role_NN of_IN pro-inflammatory_JJ
        cytokines_NNS in_IN RA_NNP ,_, anti-tumor_JJ necrosis_NNS factor-α_JJ (_( anti-_NN TNF-α_NNP )_)
        and_CC anti-interleukin_JJ 1_CD (_( anti-_NN IL-_NNP 1_LS )_) therapies_NNS can_MD reduce_VB
        inflammation_NN and_CC retard_VB the_DT progression_NN of_IN disease_NN as_IN
        assessed_VBN radiographically_RB [_NN 15_CD 16_CD ]_NN ._. However_RB ,_, side-effects_JJ
        with_IN these_DT approaches_NNS ,_, such_JJ as_IN the_DT development_NN of_IN lymphomas_NNS
        in_IN patients_NNS using_VBG anti-_NN TNF-α_NNP therapies_NNS ,_, demonstrate_VB that_IN
        alternative_JJ therapies_NNS are_VBP needed_VBN [_NN 17_CD ]_NN ._.
        An_DT alternative_JJ approach_NN to_TO the_DT prevention_NN of_IN cartilage_NN
        degradation_NN is_VBZ the_DT inhibition_NN of_IN MMPs_NNP by_IN targeting_VBG either_DT
        the_DT expression_NN of_IN their_PRP$ genes_NNS or_CC the_DT synthesis_NN of_IN the_DT
        proteins_NNS ._. Triterpenoids_NNP are_VBP a_DT novel_NN family_NN of_IN steroid-like_JJ
        compounds_NNS with_IN weak_JJ anti-inflammatory_JJ properties_NNS [_NN 18_CD ]_NN ._.
        Synthetic_NNP triterpenoids_NNS have_VBP been_VBN produced_VBN with_IN the_DT aim_NN of_IN
        achieving_VBG increased_VBN potency_NN [_NN 19_CD 20_CD ]_NN ._.
        2_CD -_: Cyano-_NNP 3_CD ,_, 12_CD -_: dioxoolean-_NN 1_CD ,_, 9_CD -_: dien-_NN 28_CD -_: oic_JJ acid_NN (_( CDDO_NNP )_) is_VBZ a_DT
        synthetic_JJ triterpenoid_NN that_WDT has_VBZ been_VBN shown_VBN to_TO inhibit_VB
        expression_NN of_IN the_DT inflammatory_JJ genes_NNS inducible_JJ nitric_JJ oxide_NN
        synthase_NN and_CC cyclo-oxygenase-_JJ 2_CD [_NN 20_CD 21_CD 22_CD ]_NN ._. In_IN a_DT recent_JJ
        report_NN ,_, MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD expression_NN were_VBD induced_VBN with_IN IL-_NNP 1_CD ,_,
        a_DT known_VBN pro-inflammatory_JJ mediator_NN 
        in_IN vivo_NN in_IN joint_JJ tissues_NNS [_NN 23_CD ]_NN ._. It_PRP
        was_VBD shown_VBN that_IN CDDO_NNP could_MD inhibit_VB the_DT IL-_NNP 1_CD -_: induced_VBN
        expression_NN of_IN these_DT pro-inflammatory_JJ MMPs_NNP ._. These_DT findings_NNS
        make_VBP CDDO_NNP an_DT attractive_JJ molecule_NN to_TO study_VB as_IN a_DT potential_JJ
        anti-arthritic_JJ agent_NN ._.
        Here_RB we_PRP report_VBP quantification_NN of_IN the_DT effects_NNS of_IN CDDO_NNP on_IN
        gene_NN expression_NN in_IN the_DT human_JJ chondrosarcoma_NN cell_NN line_NN
        SW-_NNP 1353_CD with_IN the_DT use_NN of_IN real-time_JJ reverse-transcriptase_JJ
        polymerase_NN chain_NN reaction_NN (_( RT-PCR_NNP )_) ._. To_TO ensure_VB that_IN the_DT
        chondroprotective_JJ effects_NNS of_IN CDDO_NNP are_VBP not_RB limited_VBN to_TO this_DT
        cell_NN line_NN ,_, we_PRP studied_VBD its_PRP$ effects_NNS on_IN human_JJ primary_JJ
        chondrocytes_NNS ._. We_PRP found_VBD that_IN ,_, at_IN concentrations_NNS that_WDT do_VBP not_RB
        induce_VB apoptosis_NNS ,_, CDDO_NNP effectively_RB inhibits_NNS the_DT induction_NN
        of_IN both_DT MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD gene_NN expression_NN by_IN IL-_NNP 1_CD in_IN these_DT
        cells_NNS ._. Whereas_IN the_DT inhibition_NN of_IN MMP-_NNP 1_CD by_IN CDDO_NNP requires_VBZ
        pretreatment_NN ,_, inhibition_NN of_IN MMP-_NNP 13_CD does_VBZ not_RB ._. We_PRP have_VBP
        recently_RB reported_VBN the_DT role_NN of_IN the_DT inhibitor_NN of_IN NF-κB_NNP (_( IκB_NNP )_)
        family_NN member_NN Bcl-_NNP 3_CD in_IN IL-_NNP 1_CD -_: induced_VBN MMP-_NNP 1_CD expression_NN [_NN 24_CD ]_NN
        ._. Here_RB we_PRP show_VBP that_DT overexpression_NN of_IN Bcl-_NNP 3_CD can_MD partly_RB
        abrogate_NN CDDO_NNP 's_POS inhibitory_NN effects_NNS on_IN MMP-_NNP 1_CD in_IN SW-_NNP 1353_CD
        cells_NNS ,_, suggesting_VBG that_IN Bcl-_NNP 3_CD might_MD be_VB a_DT target_NN for_IN
        CDDO_NNP ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Materials_NNS ,_, cells_NNS and_CC cell_NN culture_NN
          CDDO_NNP was_VBD kindly_RB provided_VBN by_IN Dr_NNP Tadashi_NNP Honda_NNP and_CC Dr_NNP
          Gordon_NNP Gribble_NNP (_( Dartmouth_NNP College_NNP ,_, Hanover_NNP ,_, NH_NNP ,_, USA_NNP )_) ._.
          Human_NNP SW-_NNP 1353_CD chondrosarcoma_NN cells_NNS were_VBD purchased_VBN from_IN
          the_DT American_NNP Type_NNP Culture_NNP Collection_NNP (_( Rockville_NNP ,_, MD_NNP ,_,
          USA_NNP )_) ._. Stable_NNP SW-_NNP 1353_CD cell_NN lines_NNS carrying_VBG a_DT pBkRSV_NN vector_NN
          with_IN a_DT Bcl-_NNP 3_CD expression_NN insert_NN were_VBD created_VBN as_IN described_VBN
          previously_RB [_NN 24_CD ]_NN ._. Freshly_NNP excised_VBD ,_, macroscopically_RB
          normal_JJ cartilage_NN and_CC synovium_NN from_IN OA_NNP patients_NNS undergoing_VBG
          knee_NN replacement_NN surgery_NN were_VBD obtained_VBN from_IN a_DT local_JJ
          orthopedic_JJ unit_NN (_( Dartmouth_NNP Hitchcock_NNP Memorial_NNP Hospital_NNP ,_,
          Lebanon_NNP ,_, NH_NNP ,_, USA_NNP )_) ._. These_DT tissues_NNS constitute_VBP waste_NN from_IN
          the_DT operations_NNS ._. Under_IN our_PRP$ current_JJ protocol_NN with_IN the_DT
          Committee_NNP for_IN Human_NNP Subjects_NNP as_IN mandated_VBN by_IN HIPPA_NNP ,_, we_PRP did_VBD
          not_RB collect_VB subject_JJ information_NN ._. We_PRP therefore_RB made_VBD no_DT
          selection_NN on_IN the_DT basis_NN of_IN age_NN or_CC sex_NN ._. Cartilage_NNP and_CC
          synovium_NN were_VBD degraded_JJ in_IN 4_CD mg_NN /_NN ml_NN collagenase_NN (_( Sigma_NNP ,_, St_NNP
          Louis_NNP ,_, MO_NNP ,_, USA_NNP )_) for_IN 16_CD hours_NNS at_IN 37_CD °_NN C_NNP ,_, with_IN shaking_VBG at_IN 90_CD
          r_LS ._. p_NN ._. m_NN ._. ,_, and_CC cells_NNS were_VBD cultured_JJ to_TO one_CD passage_NN
          (_( chondrocytes_NNS )_) or_CC four_CD passages_NNS (_( synovial_NN
          fibroblasts_NNS )_) ._.
          SW-_NNP 1353_CD cells_NNS (_( normal_JJ or_CC stably_RB transfected_JJ with_IN
          pBkRSV-Bcl-_JJ 3_LS )_) ,_, human_JJ primary_JJ chondrocytes_NNS ,_, or_CC synovial_NN
          fibroblasts_NNS were_VBD cultured_JJ in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS
          medium_NN (_( DMEM_NNP )_) supplemented_JJ with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN
          (_( Hyclone_NNP ,_, Logan_NNP ,_, UT_NNP ,_, USA_NNP )_) ,_, penicillin_NN /_NN streptomycin_NN and_CC
          L-_NNP glutamine_NN (_( Cellgro_NNP ;_: Mediatech_NNP ,_, Herndon_NNP ,_, VA_NNP ,_, USA_NNP )_) before_IN
          use_NN in_IN experiments_NNS ._.
        
        
          Assay_NNP of_IN CDDO_NNP 's_POS effects_NNS on_IN chondrocytes_NNS and_CC
          fibroblasts_NNS
          At_IN the_DT beginning_NN of_IN each_DT experiment_NN ,_, chondrocytes_NNS or_CC
          OA_NNP synovial_NN fibroblasts_NNS were_VBD washed_VBN three_CD times_NNS with_IN
          Hanks_NNP balanced_JJ salt_NN solution_NN (_( Cellgro_NNP )_) to_TO remove_VB traces_NNS
          of_IN serum_NN ,_, and_CC placed_VBD in_IN DMEM_NNP containing_VBG 0_CD ._. 2_CD %_NN lactalbumin_NN
          hydrolysate_NN (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Cells_NNP were_VBD
          cultured_JJ for_IN 24_CD hours_NNS with_IN CDDO_NNP as_IN a_DT pretreatment_NN ,_, or_CC
          CDDO_NNP was_VBD added_VBN at_IN the_DT same_JJ time_NN as_IN 10_CD ng_NN /_NN ml_NN recombinant_JJ
          IL-_NNP 1_CD β_NN at_IN time_NN 0_CD (_( Promega_NNP ,_, Madison_NNP ,_, WI_NNP ,_, USA_NNP )_) ._. After_IN a_DT
          further_JJ 18_CD hours_NNS of_IN culture_NN with_IN IL-_NNP 1_CD ,_, total_JJ RNA_NNP was_VBD
          harvested_VBN with_IN TRIzol_NNP (_( Invitrogen_NNP )_) and_CC assayed_JJ for_IN MMP-_NNP 1_CD ,_,
          MMP-_NNP 13_CD ,_, and_CC Bcl-_NNP 3_CD expression_NN by_IN using_VBG quantitative_JJ
          real-time_JJ RT-PCR_NNP ._. Glyceraldehyde-_NNP 3_CD -_: phosphate_NN
          dehydrogenase_NN (_( GAPDH_NNP )_) was_VBD assayed_JJ to_TO normalize_VB data_NNS ._.
          Reverse_VBP transcription_NN and_CC quantitative_JJ real-time_JJ PCR_NNP
          methods_NNS were_VBD as_IN described_VBN previously_RB [_NN 24_CD ]_NN ._. MMP-_NNP 13_CD
          primers_NNS used_VBN were_VBD as_IN follows_VBZ :_: upper_JJ ,_,
          5_CD '_POS -_: TGGCATTGCTGACATCATGA-_NNP 3_CD '_POS ;_: lower_RBR ,_,
          3_CD '_POS -_: GCCAGAGGGCCCATCAA-_NNP 5_CD '_'' ._. The_DT product_NN size_NN was_VBD 76_CD base_NN
          pairs_NNS ._. A_DT plasmid_NN containing_VBG MMP-_NNP 13_CD cDNA_NN (_( provided_VBN by_IN Dr_NNP
          Carlos_NNP Lopez-_NNP Otin_NNP ,_, Oviedo_NNP ,_, Spain_NNP )_) was_VBD used_VBN to_TO generate_VB an_DT
          MMP-_NNP 13_CD standard_JJ curve_NN ._. Primers_NNP and_CC standards_NNS for_IN MMP-_NNP 1_CD ,_,
          Bcl-_NNP 3_CD ,_, and_CC GAPDH_NNP were_VBD as_IN described_VBN previously_RB [_NN 24_CD ]_NN ._.
          The_DT generation_NN and_CC use_NN of_IN standard_JJ curves_NNS were_VBD as_IN
          described_VBN previously_RB [_NN 24_CD ]_NN ._.
        
        
          Measurement_NNP of_IN programmed_VBN cell_NN death_NN by_IN staining_VBG
          with_IN Hoechst_NNP 33342_CD
          SW-_NNP 1353_CD and_CC human_JJ primary_JJ chondrocytes_NNS were_VBD seeded_VBN at_IN
          5_CD ×_NN 10_CD 4_CD cells_NNS per_IN well_RB in_IN 24_CD -_: well_RB plates_NNS (_( Becton_NNP
          Dickinson_NNP ,_, Franklin_NNP Lakes_NNP ,_, NJ_NNP ,_, USA_NNP )_) ._. At_IN 60_CD -_: 90_CD %_NN
          confluence_NN ,_, cells_NNS were_VBD treated_VBN with_IN CDDO_NNP (_( 10_CD nM_NN to_TO 10_CD μM_NN )_)
          for_IN 24_CD hours_NNS ,_, followed_VBN by_IN IL-_NNP 1_CD for_IN 18_CD hours_NNS ._. Hoechst_NNP
          33342_CD (_( Sigma_NNP )_) (_( 1_CD μg_NN /_NN ml_NN )_) was_VBD then_RB added_VBN to_TO each_DT well_RB to_TO
          detect_VB cells_NNS with_IN condensed_JJ chromatin_NN ,_, a_DT hallmark_NN of_IN
          programmed_VBN cell_NN death_NN ._. After_IN 30_CD minutes_NNS of_IN incubation_NN at_IN
          37_CD °_NN C_NNP ,_, cells_NNS were_VBD examined_VBN under_IN a_DT fluorescent_NN microscope_NN
          as_IN described_VBN previously_RB [_NN 24_CD ]_NN ._.
        
        
          Statistical_NNP analysis_NN
          Analyses_NNS of_IN real-time_JJ PCR_NNP data_NNS were_VBD performed_VBN with_IN
          unpaired_JJ two-tailed_JJ Student_NNP 's_POS 
          t_NN -_: tests_NNS on_IN triplicate_NN wells_NNS
          cultured_JJ simultaneously_RB ._.
        
      
      
        Results_NNS
        
          Effects_NNPS of_IN CDDO_NNP in_IN SW-_NNP 1353_CD cells_NNS
          Previous_JJ work_NN suggested_VBD that_DT preincubation_NN with_IN CDDO_NNP
          was_VBD required_VBN for_IN the_DT effective_JJ inhibition_NN of_IN IL-_NNP 1_CD -_: induced_VBN
          MMP_NNP gene_NN expression_NN in_IN SW-_NNP 1353_CD cells_NNS [_NN 23_CD ]_NN ._. To_TO quantify_VB
          the_DT effect_NN of_IN altering_VBG the_DT period_NN of_IN CDDO_NNP preincubation_NN ,_,
          300_CD nM_NN CDDO_NNP was_VBD added_VBN to_TO SW-_NNP 1353_CD cells_NNS simultaneously_RB
          with_IN IL-_NNP 1_CD ,_, or_CC 24_CD hours_NNS before_IN treatment_NN with_IN the_DT
          cytokine_NN ._. We_PRP found_VBD that_IN SW-_NNP 1353_CD cells_NNS expressed_VBD very_RB low_JJ
          basal_NN levels_NNS of_IN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD ,_, and_CC that_IN these_DT were_VBD not_RB
          significantly_RB affected_VBN by_IN incubation_NN with_IN CDDO_NNP (_( Fig_NNP ._. 1_LS )_) ._.
          IL-_NNP 1_CD induced_VBD the_DT expression_NN of_IN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD ,_, and_CC
          these_DT were_VBD significantly_RB inhibited_VBD when_WRB the_DT cultures_NNS were_VBD
          pretreated_JJ with_IN CDDO_NNP for_IN 24_CD hours_NNS ,_, the_DT respective_JJ
          decreases_NNS being_VBG 55_CD %_NN for_IN MMP-_NNP 1_CD (_( 
          P_NN <_NN 0_CD ._. 1_LS )_) and_CC 66_CD %_NN for_IN MMP-_NNP 13_CD (_( 
          P_NN <_NN 0_CD ._. 01_CD )_) ._. In_IN addition_NN ,_, when_WRB
          added_VBD simultaneously_RB with_IN the_DT cytokine_NN ,_, CDDO_NNP
          significantly_RB inhibited_VBD the_DT IL-_NNP 1_CD -_: induced_VBN expression_NN of_IN
          MMP-_NNP 13_CD ,_, but_CC not_RB that_IN of_IN MMP-_NNP 1_CD ._. Under_IN these_DT circumstances_NNS ,_,
          MMP-_NNP 13_CD expression_NN was_VBD decreased_VBN by_IN 41_CD %_NN (_( 
          P_NN <_NN 0_CD ._. 05_CD )_) ._. The_DT different_JJ
          profiles_NNS for_IN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD inhibition_NN when_WRB CDDO_NNP was_VBD
          added_VBN simultaneously_RB with_IN the_DT cytokine_NN suggest_VBP a_DT
          difference_NN in_IN the_DT action_NN of_IN the_DT inhibitor_NN on_IN the_DT
          expression_NN of_IN each_DT enzyme_NN ._.
          Previously_RB ,_, with_IN the_DT use_NN of_IN Northern_NNP blotting_VBG ,_,
          dose-response_JJ assays_NNS in_IN SW-_NNP 1353_CD cells_NNS showed_VBD that_IN 300_CD nM_NN
          was_VBD the_DT lowest_JJS dose_NN of_IN CDDO_NNP sufficient_JJ to_TO decrease_VB the_DT
          IL-_NNP 1_CD -_: induced_VBN expression_NN of_IN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD [_NN 23_CD ]_NN ._. This_DT
          was_VBD confirmed_VBN by_IN using_VBG quantitative_JJ real-time_JJ PCR_NNP ._. Doses_NNP
          below_IN 300_CD nM_NN did_VBD not_RB decrease_VB MMP_NNP expression_NN ,_, whereas_IN
          those_DT above_IN 1_CD μM_NN resulted_VBD in_IN poor_NNP RNA_NNP harvests_NNS and_CC low_JJ
          expression_NN of_IN the_DT MMPs_NNP (_( data_NNS not_RB shown_VBN )_) ._. This_DT effect_NN at_IN
          higher_JJR doses_NNS might_MD be_VB due_JJ to_TO the_DT reported_VBD apoptotic_JJ
          effects_NNS of_IN CDDO_NNP [_NN 25_CD 26_CD ]_NN ._. To_TO examine_VB for_IN such_JJ effects_NNS ,_,
          SW-_NNP 1353_CD cells_NNS were_VBD treated_VBN for_IN 24_CD hours_NNS with_IN CDDO_NNP under_IN
          serum-free_JJ conditions_NNS ,_, and_CC then_RB IL-_NNP 1_CD was_VBD added_VBN for_IN a_DT
          further_JJ 18_CD hours_NNS ._. Cells_NNP were_VBD stained_JJ with_IN Hoechst_NNP 33342_CD
          and_CC examined_VBD under_IN a_DT fluorescent_NN microscope_NN ._. Doses_NNP of_IN 300_CD
          nM_NN and_CC 1_CD μM_NN CDDO_NNP ,_, with_IN or_CC without_IN IL-_NNP 1_CD ,_, did_VBD not_RB increase_VB
          apoptosis_NNS compared_VBN with_IN control_NN (_( medium_NN alone_RB )_) or_CC IL-_NNP 1_CD
          (_( data_NNS not_RB shown_VBN )_) ._. However_RB ,_, a_DT dose_NN of_IN 5_CD μM_NN caused_VBD
          apoptosis_NNS in_IN SW-_NNP 1353_CD cells_NNS ,_, as_IN seen_VBN in_IN lower_JJR cell_NN
          numbers_NNS ,_, changed_VBN morphology_NN and_CC an_DT increased_VBN number_NN of_IN
          fluorescing_VBG cells_NNS ._. These_DT data_NNS demonstrate_VBP that_IN at_IN 300_CD nM_NN
          and_CC 1_CD μM_NN ,_, doses_NNS that_WDT inhibit_VBP MMP_NNP gene_NN expression_NN ,_, CDDO_NNP
          does_VBZ not_RB cause_VB programmed_VBN cell_NN death_NN ._.
        
        
          CDDO_NNP time-course_JJ in_IN human_JJ primary_JJ
          chondrocytes_NNS
          As_IN described_VBD in_IN the_DT Introduction_NNP ,_, the_DT aim_NN of_IN studying_VBG
          the_DT triterpenoids_NNS is_VBZ to_TO develop_VB a_DT therapeutic_JJ agent_NN for_IN
          the_DT treatment_NN of_IN arthritis_NN ._. We_PRP were_VBD therefore_RB interested_JJ
          in_IN studying_VBG the_DT effects_NNS of_IN CDDO_NNP in_IN human_JJ primary_JJ cells_NNS ._.
          Quantitative_NNP real-time_JJ RT-PCR_NNP revealed_VBD that_IN human_JJ
          chondrocytes_NNS expressed_VBD low_JJ levels_NNS of_IN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD in_IN
          the_DT absence_NN of_IN IL-_NNP 1_CD ,_, and_CC increased_VBN levels_NNS with_IN addition_NN
          of_IN the_DT cytokine_NN (_( Figs_NNP 2_CD a_DT ,_, 2_CD b_SYM )_) ._. Pretreatment_NNP of_IN cultures_NNS
          with_IN 300_CD nM_NN CDDO_NNP for_IN 24_CD hours_NNS resulted_VBD in_IN a_DT decreased_VBN
          expression_NN of_IN IL-_NNP 1_CD -_: induced_VBN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD ._. MMP-_NNP 1_CD
          expression_NN was_VBD decreased_VBN by_IN 99_CD %_NN (_( 
          P_NN <_NN 0_CD ._. 01_CD )_) and_CC MMP-_NNP 13_CD by_IN 96_CD %_NN (_( 
          P_NN <_NN 0_CD ._. 01_CD )_) ._. As_IN was_VBD observed_VBN with_IN
          SW-_NNP 1353_CD cells_NNS ,_, MMP-_NNP 13_CD expression_NN was_VBD significantly_RB
          decreased_VBN when_WRB CDDO_NNP was_VBD added_VBN simultaneously_RB with_IN the_DT
          cytokine_NN :_: we_PRP observed_VBD a_DT decrease_NN of_IN 67_CD %_NN (_( 
          P_NN <_NN 0_CD ._. 1_LS )_) ._. MMP-_NNP 1_CD expression_NN was_VBD
          not_RB significantly_RB inhibited_VBD by_IN CDDO_NNP added_VBD simultaneously_RB
          with_IN IL-_NNP 1_CD ._.
        
        
          Effects_NNPS of_IN CDDO_NNP on_IN expression_NN of_IN Bcl-_NNP 3_CD in_IN human_JJ
          primary_JJ chondrocytes_NNS
          In_IN the_DT same_JJ time-course_JJ experiment_NN ,_, we_PRP assayed_JJ for_IN the_DT
          presence_NN of_IN Bcl-_NNP 3_CD ,_, an_DT IκB_NNP family_NN member_NN that_IN we_PRP have_VBP
          previously_RB shown_VBN to_TO have_VB a_DT role_NN in_IN MMP-_NNP 1_CD expression_NN ._. We_PRP
          found_VBD that_IN Bcl-_NNP 3_CD was_VBD inducible_JJ with_IN IL-_NNP 1_CD in_IN human_JJ primary_JJ
          chondrocytes_NNS ,_, and_CC that_IN CDDO_NNP significantly_RB inhibited_VBD this_DT
          expression_NN (_( Fig_NNP ._. 2_LS c_SYM )_) ._. In_IN a_DT similar_JJ manner_NN to_TO MMP-_NNP 1_CD
          inhibition_NN ,_, the_DT decreased_VBN expression_NN was_VBD observed_VBN only_RB
          after_IN preincubation_NN of_IN the_DT cells_NNS with_IN CDDO_NNP for_IN 24_CD hours_NNS
          (_( Figs_NNP 2_CD a_DT ,_, 2_CD c_SYM )_) ._. This_DT was_VBD in_IN contrast_NN to_TO MMP-_NNP 13_CD ,_, whose_WP$
          inhibition_NN was_VBD possible_JJ without_IN pretreatment_NN with_IN CDDO_NNP
          (_( Fig_NNP ._. 2_LS b_SYM )_) ._. These_DT results_NNS present_JJ further_JJ evidence_NN of_IN a_DT
          link_NN in_IN MMP-_NNP 1_CD and_CC Bcl-_NNP 3_CD expression_NN ,_, and_CC indicate_VBP that_IN
          both_DT molecules_NNS are_VBP similarly_RB affected_VBN by_IN CDDO_NNP ._.
        
        
          CDDO_NNP dose-response_JJ study_NN in_IN human_JJ primary_JJ
          chondrocytes_NNS
          To_TO examine_VB the_DT effects_NNS of_IN increasing_VBG doses_NNS of_IN CDDO_NNP in_IN
          human_JJ primary_JJ chondrocytes_NNS ,_, cells_NNS were_VBD preincubated_JJ for_IN
          24_CD hours_NNS with_IN CDDO_NNP (_( 300_CD nM_NN to_TO 5_CD μM_NN )_) ,_, or_CC with_IN medium_NN
          alone_RB ,_, before_IN the_DT addition_NN of_IN IL-_NNP 1_CD for_IN 18_CD hours_NNS ._. Figure_NN
          3_CD shows_VBZ that_IN human_JJ primary_JJ chondrocytes_NNS have_VBP low_JJ basal_NN
          expression_NN of_IN MMP-_NNP 1_CD ,_, MMP-_NNP 13_CD and_CC Bcl-_NNP 3_CD ,_, and_CC that_IN they_PRP are_VBP
          increased_VBN in_IN the_DT presence_NN of_IN IL-_NNP 1_CD ._. Increasing_VBG doses_NNS of_IN
          CDDO_NNP resulted_VBD in_IN a_DT decreased_VBN expression_NN of_IN each_DT gene_NN ._. For_IN
          example_NN ,_, MMP-_NNP 1_CD expression_NN was_VBD inhibited_VBD by_IN 36_CD %_NN (_( 
          P_NN <_NN 0_CD ._. 1_LS )_) with_IN 300_CD nM_NN CDDO_NNP ,_, by_IN
          49_CD %_NN (_( 
          P_NN <_NN 0_CD ._. 01_CD )_) with_IN 1_CD μM_NN CDDO_NNP ,_, and_CC by_IN
          83_CD %_NN (_( 
          P_NN <_NN 0_CD ._. 01_CD )_) by_IN 5_CD μM_NN CDDO_NNP ._. Similar_JJ
          patterns_NNS emerged_VBD for_IN MMP-_NNP 13_CD (_( 63_CD %_NN ,_, 81_CD %_NN ,_, and_CC 99_CD %_NN )_) and_CC Bcl-_NNP 3_CD
          (_( 33_CD %_NN ,_, 61_CD %_NN ,_, and_CC 86_CD %_NN )_) in_IN response_NN to_TO the_DT respective_JJ doses_NNS
          of_IN CDDO_NNP ,_, all_DT results_NNS being_VBG significant_JJ ._. Using_VBG Hoechst_NNP
          33342_CD ,_, we_PRP assayed_JJ for_IN potential_JJ toxicity_NN of_IN CDDO_NNP in_IN human_JJ
          primary_JJ chondrocytes_NNS :_: we_PRP found_VBD decreased_VBN cell_NN numbers_NNS and_CC
          increased_VBN apoptosis_NNS at_IN or_CC above_IN 5_CD μM_NN CDDO_NNP (_( data_NNS not_RB
          shown_VBN )_) ._. Lower_JJR concentrations_NNS did_VBD not_RB result_VB in_IN
          apoptosis_NNS ._.
        
        
          Inhibition_NNP of_IN MMP-_NNP 1_CD ,_, MMP-_NNP 13_CD ,_, and_CC Bcl-_NNP 3_CD in_IN OA_NNP
          synovial_NN fibroblasts_NNS
          In_IN parallel_JJ with_IN the_DT study_NN on_IN human_JJ primary_JJ
          chondrocytes_NNS ,_, we_PRP examined_VBD the_DT effects_NNS of_IN 300_CD nM_NN CDDO_NNP on_IN
          synovial_NN fibroblasts_NNS excised_VBD from_IN OA_NNP synovium_NN ._. There_EX were_VBD
          low_JJ basal_NN expressions_NNS of_IN MMP-_NNP 1_CD ,_, MMP-_NNP 13_CD ,_, and_CC Bcl-_NNP 3_CD ,_, which_WDT
          were_VBD increased_VBN in_IN the_DT presence_NN of_IN IL-_NNP 1_CD and_CC inhibited_VBD by_IN
          CDDO_NNP ,_, following_VBG the_DT trends_NNS observed_VBD in_IN SW-_NNP 1353_CD and_CC human_JJ
          primary_JJ chondrocytes_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Effect_NN of_IN overexpression_NN of_IN Bcl-_NNP 3_CD on_IN the_DT inhibition_NN
          of_IN MMP-_NNP 1_CD by_IN CDDO_NNP
          To_TO examine_VB further_VB the_DT role_NN of_IN Bcl-_NNP 3_CD in_IN IL-_NNP 1_CD -_: induced_VBN
          MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD expression_NN ,_, we_PRP used_VBD SW-_NNP 1353_CD cells_NNS stably_RB
          transfected_JJ with_IN a_DT Bcl-_NNP 3_CD expression_NN construct_VB ._. These_DT
          cells_NNS were_VBD pretreated_JJ with_IN 300_CD nM_NN CDDO_NNP for_IN 24_CD hours_NNS and_CC
          then_RB cultured_JJ with_IN IL-_NNP 1_CD for_IN 18_CD hours_NNS ._. In_IN the_DT presence_NN of_IN
          empty_JJ vector_NN ,_, IL-_NNP 1_CD induced_VBD both_DT MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD ,_, and_CC
          their_PRP$ expression_NN was_VBD decreased_VBN by_IN CDDO_NNP by_IN 48_CD %_NN and_CC 46_CD %_NN ,_,
          respectively_RB (_( Fig_NNP ._. 4_LS )_) ._. In_IN cells_NNS stably_RB transfected_JJ with_IN
          the_DT Bcl-_NNP 3_CD expression_NN plasmid_NN ,_, IL-_NNP 1_CD induced_VBN MMP-_NNP 1_CD
          expression_NN to_TO levels_NNS 3_CD ._. 4_CD -_: fold_VB higher_JJR than_IN in_IN the_DT cells_NNS
          transfected_JJ with_IN empty_JJ vector_NN (_( Fig_NNP ._. 4_LS a_DT )_) ._. In_IN comparison_NN ,_,
          MMP-_NNP 13_CD expression_NN was_VBD not_RB significantly_RB altered_VBN by_IN the_DT
          overexpression_NN of_IN Bcl-_NNP 3_CD (_( Fig_NNP ._. 4_LS b_SYM )_) ._. Furthermore_RB ,_, the_DT
          presence_NN of_IN exogenous_JJ Bcl-_NNP 3_CD sustained_VBN MMP-_NNP 1_CD expression_NN in_IN
          the_DT presence_NN of_IN CDDO_NNP in_IN comparison_NN with_IN cells_NNS expressing_VBG
          empty_JJ vector_NN ._. When_WRB cultured_JJ in_IN the_DT presence_NN of_IN IL-_NNP 1_CD and_CC
          CDDO_NNP ,_, cells_NNS transfected_JJ with_IN Bcl-_NNP 3_CD expressed_VBD 3_CD ._. 6_CD -_: fold_VB
          more_JJR MMP-_NNP 1_CD than_IN did_VBD cells_NNS transfected_JJ with_IN the_DT empty_JJ
          vector_NN (_( Fig_NNP ._. 4_LS a_DT )_) ._. In_IN contrast_NN ,_, Bcl-_NNP 3_CD did_VBD not_RB sustain_VB
          MMP-_NNP 13_CD expression_NN in_IN CDDO-treated_NNP cells_NNS (_( Fig_NNP ._. 4_LS b_SYM )_) ._. Thus_RB ,_,
          Bcl-_NNP 3_CD ,_, which_WDT is_VBZ repressed_VBN by_IN CDDO_NNP ,_, preferentially_RB
          contributes_VBZ to_TO MMP-_NNP 1_CD gene_NN expression_NN ._.
        
      
      
        Discussion_NNP
        In_IN a_DT previous_JJ study_NN ,_, Northern_NNP blot_NN analysis_NN showed_VBD that_IN
        treating_VBG SW-_NNP 1353_CD cells_NNS with_IN 300_CD nM_NN CDDO_NNP for_IN 24_CD hours_NNS before_IN
        treatment_NN with_IN IL-_NNP 1_CD inhibited_VBD the_DT expression_NN of_IN MMP-_NNP 1_CD and_CC
        MMP-_NNP 13_CD [_NN 23_CD ]_NN ._. In_IN the_DT present_JJ study_NN we_PRP used_VBD quantitative_JJ
        real-time_JJ RT-PCR_NNP to_TO examine_VB the_DT action_NN of_IN CDDO_NNP on_IN the_DT
        expression_NN of_IN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD in_IN SW-_NNP 1353_CD cells_NNS and_CC in_IN two_CD
        primary_JJ cultures_NNS :_: human_JJ primary_JJ chondrocytes_NNS and_CC OA_NNP
        synovial_NN fibroblasts_NNS ._. We_PRP have_VBP shown_VBN in_IN a_DT quantitative_JJ
        manner_NN that_IN in_IN all_DT three_CD cell_NN types_NNS ,_, MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD are_VBP
        inducible_JJ with_IN IL-_NNP 1_CD ,_, and_CC that_IN CDDO_NNP inhibits_NNS the_DT expression_NN
        of_IN these_DT collagenases_NNS ,_, with_IN optimal_NN inhibition_NN being_VBG
        observed_VBN after_IN 24_CD hours_NNS of_IN pretreatment_NN with_IN CDDO_NNP ._.
        Differing_NNP effects_NNS were_VBD found_VBN on_IN the_DT two_CD enzymes_NNS :_: MMP-_NNP 13_CD was_VBD
        inhibited_VBD more_JJR than_IN MMP-_NNP 1_CD ._. In_IN addition_NN ,_, significant_JJ
        inhibition_NN of_IN MMP-_NNP 13_CD did_VBD not_RB require_VB the_DT pretreatment_NN of_IN
        cells_NNS with_IN CDDO_NNP ._. In_IN addition_NN ,_, the_DT observation_NN that_IN synovial_NN
        fibroblasts_NNS respond_VBP to_TO CDDO_NNP in_IN a_DT similar_JJ manner_NN to_TO
        chondrocytes_NNS suggests_VBZ that_IN the_DT inhibitor_NN can_MD act_VB in_IN all_DT
        cells_NNS of_IN the_DT joint_NN to_TO decrease_VB the_DT expression_NN of_IN MMP-_NNP 1_CD and_CC
        MMP-_NNP 13_CD ._.
        In_IN the_DT human_JJ primary_JJ chondrocytes_NNS and_CC OA_NNP synovial_NN
        fibroblasts_NNS ,_, we_PRP assayed_JJ for_IN CDDO_NNP 's_POS effects_NNS on_IN Bcl-_NNP 3_CD
        expression_NN ._. We_PRP have_VBP recently_RB described_VBN the_DT role_NN of_IN Bcl-_NNP 3_CD ,_,
        an_DT IκB_NNP family_NN member_NN ,_, in_IN the_DT signaling_VBG pathways_NNS of_IN IL-_NNP 1_CD
        leading_VBG to_TO MMP-_NNP 1_CD expression_NN in_IN SW-_NNP 1353_CD cells_NNS and_CC rabbit_NN
        synovial_NN fibroblasts_NNS [_NN 24_CD ]_NN ._. We_PRP found_VBD that_IN IL-_NNP 1_CD could_MD
        induce_VB the_DT expression_NN of_IN Bcl-_NNP 3_CD ,_, and_CC that_IN Bcl-_NNP 3_CD had_VBD a_DT direct_JJ
        effect_NN on_IN MMP-_NNP 1_CD expression_NN through_IN cooperation_NN with_IN
        NF-κB_NNP 1_CD /_NN p_NN 50_CD ._. In_IN the_DT present_JJ study_NN we_PRP found_VBD that_IN Bcl-_NNP 3_CD
        expression_NN was_VBD inducible_JJ by_IN IL-_NNP 1_CD in_IN human_JJ primary_JJ
        chondrocytes_NNS and_CC in_IN OA_NNP synovial_NN fibroblasts_NNS ._. In_IN addition_NN ,_,
        we_PRP found_VBD that_DT pretreatment_NN with_IN CDDO_NNP decreased_VBD the_DT
        IL-_NNP 1_CD -_: induced_VBN expression_NN of_IN Bcl-_NNP 3_CD in_IN these_DT cells_NNS ._.
        Furthermore_RB ,_, with_IN the_DT use_NN of_IN SW-_NNP 1353_CD cells_NNS stably_RB
        transfected_JJ with_IN a_DT Bcl-_NNP 3_CD expression_NN plasmid_NN ,_, Bcl-_NNP 3_CD could_MD
        sustain_VB the_DT expression_NN of_IN MMP-_NNP 1_CD ,_, but_CC not_RB that_IN of_IN MMP-_NNP 13_CD ,_,
        against_IN inhibition_NN by_IN CDDO_NNP ._. These_DT data_NNS show_VBP that_IN Bcl-_NNP 3_CD gene_NN
        expression_NN is_VBZ a_DT target_NN of_IN CDDO_NNP in_IN chondrocytes_NNS and_CC suggest_VBP
        that_IN this_DT might_MD contribute_VB to_TO decreased_VBD MMP-_NNP 1_CD expression_NN ._.
        Consistent_NNP with_IN this_DT model_NN is_VBZ the_DT finding_VBG that_DT pretreatment_NN
        with_IN CDDO_NNP for_IN 24_CD hours_NNS is_VBZ required_VBN for_IN the_DT inhibition_NN of_IN
        MMP-_NNP 1_CD ,_, unlike_IN that_DT for_IN MMP-_NNP 13_CD ._. We_PRP speculate_VBP that_RB ,_, during_IN
        this_DT period_NN ,_, the_DT inhibitor_NN is_VBZ entering_VBG the_DT cell_NN and_CC
        altering_VBG the_DT expression_NN of_IN components_NNS of_IN the_DT IL-_NNP 1_CD
        signalling_VBG pathway_NN ._. Bcl-_NNP 3_CD is_VBZ decreased_VBN by_IN CDDO_NNP during_IN this_DT
        preincubation_NN period_NN ,_, and_CC it_PRP might_MD be_VB one_CD of_IN several_JJ
        proteins_NNS involved_VBN in_IN MMP_NNP expression_NN whose_WP$ own_JJ expression_NN is_VBZ
        lowered_VBN by_IN CDDO_NNP ._.
        In_IN all_DT cell_NN types_NNS ,_, CDDO_NNP inhibited_VBD the_DT IL-_NNP 1_CD -_: induced_VBN
        expression_NN of_IN MMP-_NNP 13_CD mRNA_NN more_RBR effectively_RB than_IN that_DT of_IN
        MMP-_NNP 1_CD ._. This_DT might_MD be_VB due_JJ to_TO the_DT much_RB lower_JJR MMP-_NNP 13_CD
        expression_NN in_IN all_DT tissues_NNS examined_VBD ._. There_EX is_VBZ disagreement_NN
        over_IN which_WDT collagenase_NN predominates_NNS in_IN cartilage_NN
        degradation_NN 
        in_IN vivo_NN [_NN 10_CD 11_CD ]_NN ._. It_PRP is_VBZ therefore_RB
        of_IN interest_NN to_TO find_VB the_DT levels_NNS of_IN MMP-_NNP 1_CD expressed_VBD compared_VBN
        with_IN that_DT of_IN MMP-_NNP 13_CD in_IN SW-_NNP 1353_CD and_CC human_JJ primary_JJ
        chondrocytes_NNS ._. For_IN example_NN ,_, in_IN human_JJ primary_JJ chondrocytes_NNS
        (_( Figs_NNP 3_CD a_DT ,_, 3_CD b_SYM )_) ,_, IL-_NNP 1_CD induced_VBN MMP-_NNP 1_CD to_TO 14_CD molecules_NNS per_IN
        molecule_NN of_IN GAPDH_NNP ,_, whereas_IN MMP-_NNP 13_CD was_VBD expressed_VBN at_IN 0_CD ._. 06_CD
        molecules_NNS per_IN molecule_NN of_IN GAPDH_NNP ,_, a_DT more_JJR than_IN 200_CD -_: fold_VB
        difference_NN ._. These_DT results_NNS suggest_VBP that_IN MMP-_NNP 1_CD expression_NN
        might_MD be_VB a_DT dominant_JJ target_NN for_IN IL-_NNP 1_CD in_IN chondrocytes_NNS ._.
        It_PRP is_VBZ interesting_JJ to_TO note_VB that_IN there_EX was_VBD significant_JJ
        variation_NN of_IN both_DT MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD expression_NN in_IN the_DT
        primary_JJ human_JJ chondrocyte_NN experiments_NNS ._. In_IN excising_VBG
        chondrocytes_NNS from_IN the_DT extracted_VBN knees_NNS of_IN OA_NNP patients_NNS ,_, great_JJ
        care_NN was_VBD taken_VBN to_TO remove_VB only_RB tissue_NN that_WDT seemed_VBD
        macroscopically_RB normal_JJ ,_, with_IN the_DT aim_NN of_IN excluding_VBG cells_NNS of_IN
        diseased_JJ tissue_NN ._. When_WRB these_DT cells_NNS were_VBD cultured_JJ with_IN medium_NN
        alone_RB ,_, they_PRP expressed_VBD low_JJ levels_NNS of_IN MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD ,_,
        similar_JJ to_TO those_DT found_VBD in_IN unstimulated_JJ SW-_NNP 1353_CD cells_NNS ._. These_DT
        results_NNS support_VBP the_DT contention_NN that_IN the_DT cells_NNS were_VBD in_IN a_DT
        basal_NN state_NN ,_, unaffected_JJ by_IN the_DT environment_NN of_IN the_DT diseased_JJ
        knee_NN from_IN which_WDT they_PRP had_VBD been_VBN extracted_VBN ._. Furthermore_RB ,_, both_DT
        enzymes_NNS were_VBD consistently_RB increased_VBN by_IN IL-_NNP 1_CD and_CC inhibited_VBD
        by_IN CDDO_NNP ._. Thus_RB ,_, the_DT observed_VBN variation_NN of_IN MMP_NNP expression_NN is_VBZ
        probably_RB due_JJ to_TO genetic_JJ variability_NN and_CC not_RB to_TO experimental_JJ
        artifacts_NNS ._.
        Naturally_RB occurring_VBG triterpenoids_NNS ,_, such_JJ as_IN ursolic_JJ acid_NN ,_,
        have_VBP been_VBN found_VBN to_TO have_VB mild_JJ anti-inflammatory_JJ effects_NNS [_NN 18_CD
        27_CD ]_NN ._. These_DT have_VBP been_VBN improved_VBN with_IN the_DT development_NN of_IN
        synthetic_JJ triterpenoids_NNS such_JJ as_IN CDDO_NNP ,_, offering_VBG a_DT potential_JJ
        therapeutic_JJ tool_NN for_IN the_DT treatment_NN of_IN arthritis_NN and_CC other_JJ
        diseases_NNS [_NN 19_CD 20_CD 21_CD ]_NN ._. Furthermore_RB ,_, it_PRP has_VBZ been_VBN reported_VBN
        that_IN CDDO_NNP at_IN high_JJ doses_NNS (_( 5_CD -_: 10_CD μM_NN )_) can_MD have_VB pro-apoptotic_JJ
        effects_NNS ,_, ideal_JJ for_IN the_DT treatment_NN of_IN leukemia_NN but_CC of_IN concern_NN
        with_IN regard_NN to_TO chondrocyte_NN cell_NN death_NN [_NN 25_CD 26_CD ]_NN ._. However_RB ,_,
        we_PRP found_VBD that_IN CDDO_NNP ,_, at_IN concentrations_NNS that_WDT decrease_VBP MMP-_NNP 1_CD
        and_CC MMP-_NNP 13_CD expression_NN (_( namely_RB 300_CD nM_NN and_CC 1_CD μM_NN )_) ,_, did_VBD not_RB
        cause_VB cell_NN death_NN ._. The_DT inhibitory_NN effect_NN of_IN CDDO_NNP on_IN MMP-_NNP 1_CD
        and_CC MMP-_NNP 13_CD expression_NN ,_, as_RB well_RB as_IN that_DT of_IN Bcl-_NNP 3_CD ,_, is_VBZ very_RB
        encouraging_VBG for_IN future_JJ applications_NNS of_IN triterpenoids_NNS in_IN
        arthritic_JJ disease_NN ._. CDDO_NNP is_VBZ an_DT early-generation_JJ synthetic_JJ
        triterpenoid_NN ,_, and_CC further_JJ modifications_NNS continue_VBP to_TO be_VB
        made_VBN ._. Further_RB analysis_NN of_IN these_DT compounds_NNS will_MD provide_VB
        additional_JJ information_NN about_IN their_PRP$ mechanisms_NNS and_CC potential_JJ
        as_IN therapeutic_JJ agents_NNS ._.
      
      
        Conclusion_NNP
        Inhibition_NNP of_IN collagen_NN loss_NN is_VBZ crucial_JJ to_TO minimizing_VBG
        cartilage_NN destruction_NN in_IN the_DT arthritides_NNS ._. MMP-_NNP 1_CD and_CC MMP-_NNP 13_CD
        have_VBP been_VBN identified_VBN as_IN the_DT significant_JJ enzymes_NNS involved_VBN in_IN
        this_DT process_NN 
        in_IN vivo_NN ._. We_PRP examined_VBD a_DT novel_NN ,_,
        synthetic_JJ triterpenoid_NN ,_, CDDO_NNP ,_, as_IN a_DT potential_JJ inhibitor_NN of_IN
        collagenase_NN expression_NN ._. We_PRP found_VBD that_IN CDDO_NNP inhibited_VBD the_DT
        expression_NN of_IN these_DT enzymes_NNS in_IN a_DT chondrocyte_NN cell_NN line_NN ,_,
        human_JJ primary_JJ chondrocytes_NNS and_CC synovial_NN fibroblasts_NNS ._.
        Furthermore_RB ,_, CDDO_NNP decreased_VBD the_DT expression_NN of_IN the_DT
        pro-inflammatory_JJ mediator_NN Bcl-_NNP 3_CD ,_, suggesting_VBG one_CD possible_JJ
        mechanism_NN of_IN action_NN ._. CDDO_NNP is_VBZ an_DT early-generation_JJ
        therapeutic_JJ agent_NN with_IN great_JJ potential_NN for_IN the_DT treatment_NN of_IN
        the_DT arthritides_NNS and_CC other_JJ inflammatory_JJ diseases_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        CDDO_NNP =_SYM 2_CD -_: cyano-_NN 3_CD ,_, 12_CD -_: dioxoolean-_NN 1_CD ,_, 9_CD -_: dien-_NN 28_CD -_: oic_JJ acid_NN ;_:
        DMEM_NNP =_SYM Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN ;_: GAPDH_NNP =_SYM
        glyceraldehyde-_NN 3_CD -_: phosphate_NN dehydrogenase_NN ;_: IκB_NNP =_SYM inhibitor_NN
        of_IN NF-κB_NNP ;_: IL_NNP =_SYM interleukin_NN ;_: MMP_NNP =_SYM matrix_NN metalloproteinase_NN ;_:
        OA_NNP =_SYM osteoarthritis_NNS ;_: RA_NNP =_SYM rheumatoid_NN arthritis_NN ;_: RT-PCR_NNP =_SYM
        reverse-transcriptase_JJ polymerase_NN chain_NN reaction_NN ;_: TNF-α_NNP =_SYM
        tumor_NN necrosis_NNS factor-α_JJ ._.
      
    
  
